On July 16, Abbott Laboratories reported Q2 sales of $12.593 billion, surpassing the consensus estimate of $12.497 billion, while adjusted EPS came in at $1.31 versus the $1.28 expected. The company also raised its full-year guidance, now projecting adjusted EPS of $5.45 to $5.60, compared to the FactSet estimate of $5.47, with full-year revenue expected at approximately $50.11 billion and organic sales growth of 6.5% to 7.5%.

The beat is particularly notable given that Abbott had previously lowered its annual earnings outlook in Q1 to $5.38-$5.58 per share, citing headwinds from weak diabetes product sales, a softer respiratory testing season, and short-term dilution from its approximately $21 billion acquisition of Exact Sciences. The Q2 results signal that the company's anticipated second-half growth acceleration is materializing, helping restore market confidence after months of stock price pressure.

Abbott Laboratories surged 12.66% in morning trading.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)